作者：李健超1，2，李树仁2，赵文静2，3，郝潇2，张飞飞2，张倩辉2，苑可心2，郝清卿2

单位：

1.075000 河北省张家口市，河北北方学院研究生学院2.050000 河北省石家庄市，河北省人民医院心血管内一科 3.050000 河北省石家庄市，河北医科大学研究生学院

Units：

1.Graduate School of Hebei North University, Zhangjiakou 075000, China2.Department of Cardiovascular Internal Medicine, Hebei General Hospital, Shijiazhuang 050000, China3.Graduate School of Hebei Medical University, Shijiazhuang 050000, China

关键词：

新型冠状病毒肺炎；抗血栓治疗；抗凝治疗；抗血小板治疗；综述

Keywords：

COVID-19; Antithrombotic therapy; Anticoagulation therapy; Antiplatelet therapy; Review

CLC：

R 512.99

DOI：

10.12114/j.issn.1008-5971.2021.00.142

Funds：

摘要：

严重急性呼吸综合征冠状病毒2（SARS-CoV-2）可通过表面的刺突蛋白（S 蛋白）对细胞造成损伤， 随后引起一系列病理生理改变，包括内皮细胞功能障碍、大量细胞因子释放、肾素- 血管紧张素系统（RAS 系统）激 活、血小板激活、凝血功能障碍等，最终导致血栓形成。新型冠状病毒肺炎（COVID-19）患者较易患血栓性疾病， 尽管采取血栓预防，但血栓栓塞仍常见，且合并血栓并发症的患者死亡率高。因此，对COVID-19 尤其是重型、危重 型或高危静脉血栓栓塞症（VTE）患者进行血栓预防及治疗至关重要。本文就COVID-19 患者的抗凝治疗和抗血小板 治疗进行综述，以期为COVID-19 患者的抗血栓治疗提供理论指导。

Abstract：

　Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can damage cells through spike protein (S protein) on the surface, then cause a series of pathophysiological changes, including the endothelial cell dysfunction, release of cytokines, renin angiotensin system (RAS system) activation, platelet activation and blood coagulation dysfunction and so on, eventually lead to thrombosis. Patients with corona virus disease 2019 (COVID-19) are prone to thrombotic disease. Despite thromboprophylaxis, thromboembolism is still common and patients with thrombotic complications have a high mortality rate. Therefore, thromboprolaxis and treatment of COVID-19 patients, especially those with moderate to severe or high risk of venous thromboembolism (VTE) , is of crucial. This article reviews the anticoagulant therapy and antiplatelet therapy for patients with COVID-19, in order to provide theoretical guidance for antithrombotic treatment of COVID-19 patients.

ReferenceList：